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Abstract
Gram-negative bacteria naturally shed particles that consist of outer membrane lipids, outer membrane proteins, and
soluble periplasmic components. These particles have been proposed for use as vaccines but the yield has been
problematic. We developed a high yielding production process of genetically derived outer membrane particles from the
human pathogen Shigella sonnei. Yields of approximately 100 milligrams of membrane-associated proteins per liter of
fermentation were obtained from cultures of S. sonnei DtolR DgalU at optical densities of 30–45 in a 5 L fermenter.
Proteomic analysis of the purified particles showed the preparation to primarily contain predicted outer membrane and
periplasmic proteins. These were highly immunogenic in mice. The production of these outer membrane particles from high
density cultivation of bacteria supports the feasibility of scaling up this approach as an affordable manufacturing process.
Furthermore, we demonstrate the feasibility of using this process with other genetic manipulations e.g. abolition of O
antigen synthesis and modification of the lipopolysaccharide structure in order to modify the immunogenicity or
reactogenicity of the particles. This work provides the basis for a large scale manufacturing process of Generalized Modules
of Membrane Antigens (GMMA) for production of vaccines from Gram-negative bacteria.
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Introduction
Shigella spp. are Gram-negative bacteria that infect the intestinal
epithelium and cause dysentery. In 1999 the World Health
Organization estimated an annual burden of 164.7 million
shigellosis cases throughout the year of which 163.2 occur in
developing countries, including 1.1 million deaths, mostly in
children younger than 5 years of age [1]. Four serogroups have
been identified: S. dysenteriae (15 serotypes), S. boydii (20 serotypes),
S. flexneri (14 serotypes) and S. sonnei (1 serotype) [2]. No vaccine is
currently available. So far, vaccine candidates based on O antigen
conjugates and live attenuated strains have been shown in clinical
trials to protect against homologous strains [2–6]. Vaccines using
inactivated bacteria or subcellular components are at various
stages of development [3,6].
Gram-negative bacteria naturally shed outer membrane parti-
cles consisting of outer membrane lipids, outer membrane
proteins, and enclosed periplasmic proteins [7–9]. Unlike most
unilamellar biological vesicles, outer membrane particles are
formed by blebbing and not by invagination of the membrane.
Thus, the orientation of components in the membrane of the outer
membrane particles is the same as in the bacterial outer
membrane and the components in the outer face of the bacterial
outer membrane are also in the outer face of the outer membrane
particles [7]. Outer membrane particles are naturally shed at low
concentration. Mutations such as the deletion of gene gna33 in
Neisseria meningitidis [10] or modifications of the tol-pal pathway of
Escherichia coli, Shigella flexneri, and Salmonella enterica serovar
Typhimurium [11,12] can increase the level of shedding.
Especially, deletion of the tolR gene in E. coli has been shown to
result in substantial overproduction of outer membrane particles
without loss of membrane integrity [11,13]. Studies have
characterized the protein content of these outer membrane
particles [10,13], and unlike conventional detergent-extracted
outer membrane vesicles derived from homogenized bacteria they
are almost free of cytoplasmic and inner membrane components
and maintain lipoproteins. The outer membrane particles used for
those proteomic studies have been derived in small quantities from
cells grown to low cell density.
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could be exploited for use as vaccines [10,12]. The immunoge-
nicity of outer membrane particles from a variety of Gram-
negative bacteria has been studied. Consistent with their high
content of stimulators of the innate immune system, e.g.
lipopolysaccharide (LPS) [7] and Toll-like receptor 2 (TLR2)
agonists [14], they are strongly immunogenic in the absence of
adjuvant. They have been shown to induce protection in mice
against multiple pathogens, including Salmonella enterica serovar
Typhimurium [15], Helicobacter pylori [16], Vibrio cholera [17,18], or
to elicit antibodies in mice with in vitro bactericidal activity, e.g. for
Neisseria meningitidis [19]. Recently, outer membrane particles from
Shigella flexneri 2a have been shown to confer protection in mice
after mucosal immunization [20]. Although these studies suggest
that outer membrane particles may form the basis of vaccines
[15,17,18], there remain several problems: their reactogenicity
and the difficulty of purifying them in the quantity and at costs
that would make them attractive as vaccines for the public sector
most impacted by diseases such as shigellosis.
The problem of reactogenicity is amenable to genetic manip-
ulation. A variety of strategies has been examined to attenuate the
pyrogenicity of LPS by modifying genes involved in lipid A
biosynthesis, e.g. msbB and htrB in Shigella and E. coli or lpxL in
Neisseria that are required for complete acylation and thereby
pyrogenicity of lipid A [21–24]. However, a major remaining
difficulty is developing a scalable method for the high volume and
low unit cost production of vaccines based on this method.
In this paper we show that high purity outer membrane
particles from Shigella sonnei mutant strains can be produced from
fermentation in chemically defined medium with high yield using a
simple purification process thus making production of inexpensive
vaccines feasible. We believe that this process will be widely
applicable for production of Gram-negative membrane antigens
and thus call it the ‘Generalized Modules for Membrane Antigens
(GMMA)’ process. In the literature, outer membrane particles that
are either naturally released or produced by genetically modified
strains are usually referred to as outer membrane vesicles (OMV).
The same term has also been used for the vesicles derived by
detergent-extraction of homogenized bacteria currently used as
vaccines, e.g. MeNZB, an outer membrane vesicle vaccine used to
control Neisseria meningitidis type B infections in New Zealand. In
order to differentiate the two substantially different types of OMV
[10] we chose the term GMMA to specify the particles released
from the surface of intact cells used in this study.
Methods
Construction of Shigella Sonnei 53G Mutants
Shigella sonnei 53G [25] was chosen as parent strain. The null
mutants tolR [13], galU [26], and msbB1 [21] were obtained by
replacing the gene coding sequence with a resistance cassette [27].
Kanamycin was used for tolR, chloramphenicol for galU and
erythromycin for msbB1. To achieve this, we used a three step
PCR protocol to fuse the gene upstream and downstream regions to
the resistance gene. Briefly, the upstream and downstream regions
of the gene were amplified from Shigella sonnei 53G genomic DNA
with the primer pairs gene.AB.500-5/gene.ABL-3 and gene.AB.L-
5/gene.AB.500-3, respectively (details of target ‘gene’, antibiotic
cassette ‘AB’ and sequence are reported in Table 1). The
kanamycin cassette was amplified from pUC4K [28] and the cat
gene from pKOBEG [29] using the primers ampli.AB-5/
ampliAB-3 (Table 1). Finally the three amplified fragments were
fused together by mixing 100 ng of each in a PCR reaction
containing the gene.AB.500-5/gene.AB.500-3 primers. The linear
fragment to delete tolR was used to transform recombination-
prone Shigella sonnei 53G carrying pAJD434 to obtain the
respective deletion mutant S. sonnei DtolR. Recombination-prone
S. sonnei DtolR was then transformed with the linear fragment for
the deletion of galU, resulting in mutant strain S. sonnei DtolR
DgalU. A clone of S. sonnei DtolR lacking the virulence plasmid,
S. sonnei –pSS DtolR, was selected by white appearance on congo
red agar. The curing of the virulence plasmid (pSS) was confirmed
by the absence of the origin of replication and the plasmid
encoded gene wzy using primers pS.so53G.oriF/pS.so53G.oriR
and pS.so53G.wzyF/pS.so53G.wzyR respectively (Table 1). Two
functional msbB genes are present in Shigella [21]. In the DtolR
background, the copy located on the virulence plasmid (msbB2)
was removed by curing the plasmid and the plasmid pDmsbBko::
ery was constructed to delete the gene msbB1 on the chromosome.
Upstream and downstream flanking regions of the msbB1 gene
were amplified by PCR with the XbaI.msbB.59.F/
EcoRV.msbB.59.R and EcoRV.msbB.39.F/XhoI.msbB.39.R prim-
ers, respectively. Both products were cloned into the pBluescript
(Stratagene) vector in Max EfficiencyH E. coli DH5a
TM-T1
R
(Invitrogen). The erm erythromycin resistance gene [30] was
amplified with primers EcoRV.Ery.F/EcoRV.Ery.R and was
inserted into the EcoRV site between the flanking regions
generating pDmsbBko::ery. Primers XbaI.msbB.59.F/
XhoI.msbB.39.R were used to amplify by PCR a linear fragment
from pDmsbBko::ery plasmid, containing the resistance cassette
flanked by msbB1 flanking regions that was used to transform the
recombination-prone plasmid-cured Shigella sonnei 53G DtolR strain
to generate the msbB knockout mutant. Recombination-prone
Table 1. Primers used in this study.
tolR.Kan.500-5 TCTGGAATCGAACTCTCTCG
tolR.Kan.L3 ATTTTGAGACACAACGTGGCTTTCATGGCTTACCCCTTGTTG
tolR.Kan.L5 TTCACGAGGCAGACCTCATAAACATCTGCGTTTCCCTTG
tolR.Kan.500-3 TTGCTTCTGCTTTAACTCGG
ampli.Kan-5 ATGAGCCATATTCAACGGGAAAC
ampli.Kan-3 TTAGAAAAACTCATCGAGCATCAAA
galU.Cm.500-5 AAAATCAACGGTTGCCAGAG
galU.Cm.L-3 CGAAGTGATCTTTCCGTCACATTAAATTCTCCTGGACTGTTC
galU.ext-5 GCCTGGTGCTTGATATTGC
galU.Cm.500-3 GCGCAGGCAAGAGAATGTA
galU.Cm.L-5 CAGTTATTGGTGCCCCATCCGTATCGGTGTTATCC
galU.ext-3 TCCTGGCTATTGCACAACT
ampli.Cm-5 TGTGACGGAAAGATCACTTCG
ampli.Cm-3 GGGCACCAATAACTGCCTTA
XbaI.msbB.59.F CTAGTCTAGAAGTGCTTTCAGTGGGTGACG
EcoRV.msbB.59.R AGCTTGATATCCCATGCTTTTCCAGTTTCGG
EcoRV.msbB.39.F AGCTTGATATCGGCGAAATCCAACCGTATAAG
XhoI.msbB.39.R CCGCTCGAGGGGGAAGTTGTTAAGACAGAC
EcoRV.Ery.F AGCTTGATATCAGAGTGTGTTGATAGTGCAGTATC
EcoRV.Ery.R AGCTTGATATCACCTCTTTAGCTTCTTGGAAGCT
pS.so53G.oriF CGTAACCGTAATTACAGCCG
pS.so53G.oriR GATTTCACCTTACCCATCCC
pS.so53G.wzyF CGTTGAGGTTTCACGTTTCT
pS.so53G.wzyR TTACCAATATACCCTCCGCA
doi:10.1371/journal.pone.0035616.t001
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proficient homologous recombination system as previously de-
scribed (red operon) [31] encoded on pAJD434 [32]. pAJD434 was
subsequently removed from the mutant strains.
Bacterial Strain Growth Conditions and Media
Shigella sonnei and E. coli strains were routinely cultured in
Luria-Bertani (LB) medium. When required, kanamycin (30 mg/
mL), chloramphenicol (20 mg/mL), trimethoprim (100 mg/mL),
or ampicillin (100 mg/mL) were added. Tryptic soy agar (30 g/L
tryptic soy broth, 15 g/L agar) supplemented with 150 mg/L
congo red was used to evaluate the presence of the virulence
plasmid in Shigella. GMMA were prepared from cultures grown
in flasks or in a 5 L fermenter (Applikon) in yeast extract
medium (HTMC) or Shigella sonnei defined medium (SSDM).
HTMC was prepared as follows: yeast extract 30 g/L, KH2PO4
5 g/L, K2HPO4 20 g/L, MgSO4*7H2O 1.2 g/L, glycerol 15 g/
L, polypropylene glycol (PPG) 0.25 g/L. SSDM was prepared as
follows: glycerol 30 g/L, KH2PO4 13.3 g/L, (NH4)2HPO4 4g /
L, MgSO4*7H2O 1.2 g/L, citric acid 1.7 g/L, CoCl2*6H2O
2.5 mg/L, MnCl2*4H2O 15 mg/L, CuCl2*2H2O 1.5 mg/L,
H3BO3 3 mg/L, Na2MoO4*2H2O 2.5 mg/L,
Zn(CH3COO)2*2H2O 13 mg/L, ferric citrate 2 mM (unless
specified differently in text), thiamine 50 mg/L, nicotinic acid
10 mg/L, L-aspartic acid 2.5 g/L, PPG 0.25 g/L. For fermen-
tation, starter cultures were grown from glycerol stocks to OD
0.8 and subsequently transferred to the 5 L fermenter to reach a
starting OD of 0.02. Dissolved oxygen was maintained at 30%
saturation by controlling agitation and setting maximum
aeration. The pH was maintained at 7.2 in HTMC or at 6.7
in SSDM, with 4 M ammonium hydroxide by a pH controller
and temperature was kept constant either at 37uCo ra t3 0 uC.
From flask cultures, supernatants were collected by 10 min
centrifugation at 4000 g followed by 0.22 mm filtration or by
tangential flow filtration. The optical density (OD) of cultures
was measured at 600 nm wavelength.
Tangential Flow Filtration Purification
A 2-step tangential flow filtration (TFF) process was used to
purify GMMA. During the first TFF step, the culture superna-
tant which contains the GMMA was separated from the bacteria
using a 0.2 mm pore size cassette (Sartocon HYDROSART
0.2 mm, Sartorius). When approximately 80% of the starting feed
was recovered as filtrate, the remaining biomass (retentate) was
washed in five diafiltration steps with phosphate buffered saline
(PBS). The GMMA-containing culture supernatant and the
GMMA-containing filtrate of the diafiltration steps were com-
bined. In a modified process the diafiltration of the biomass was
omitted. Experiments performed without this diafiltration step
are specified in the text. In the second step, the combined filtrate
was micro-filtered using a 0.1 mm pore size membrane (Sartocon
SLICE 200 0.1 mm, Sartorius) in order to separate GMMA that
remain in the retentate from soluble proteins (filtrate). After five
diafiltration steps using PBS, the retentate containing the
GMMA was collected and sterile filtered using a 0.22 mm
Express
TM PLUS stericup (Millipore).
Protein Quantification
Proteins were quantified by Bradford method, using bovine
serum albumin as standard. GMMA were boiled for 10 minutes in
3.0 M guanidine hydrochloride prior quantification.
Negative Staining Electron Microscopy
A drop of 5 mL of GMMA suspension was placed on copper
formvar/carbon-coated grids and adsorbed for 5 min. Grids were
then washed with few drops of distilled water and blotted with a
Whatman filter paper. For negative staining, grids were treated
with 2% uranyl acetate in ddH2O for 1 min, air-dried and viewed
with a CM100 transmission electron microscope (Philips, Eindo-
ven, the Netherlands) operating at 80 kV. Electron micrographs
were recorded at a nominal magnification of 600006.
Denaturing Mono-Dimensional Electrophoresis
GMMA were denatured for 3 min at 95uC in sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer containing 2% (wt/vol) SDS. 20 mg of proteins were loaded
onto 12% (wt/vol) or 4–12% (wt/vol) polyacrylamide gels
(BioRad, Hercules, U.S.A.). Gels were run in 3-(N-morpholino)-
propanesulfonic acid (MOPS) buffer (BioRad) and were stained
with Coomassie Blue R-250.
Two-Dimensional Electrophoresis
Two hundred micrograms of GMMA were separated by 2-
dimentional electrophoresis (2-DE) as previously described [10].
Briefly, proteins were separated in the first dimension on a non
linear pH 3–11 gradient and in the second dimension on a linear
4–12% polyacrylamide gradient unless specified in text. Gels were
stained with colloidal Coomassie G-250 [33].
Densitometry Analysis
SDS-PAGE and 2-DE gels were scanned with an Image Quant
400 (GE Healthcare). Images were analyzed with the software
Image master 2D Platinum 6.0 (Amersham Biosciences).
In-Gel Protein Digestion and MALDI-TOF Analysis
Protein spots were excised from the gels and processed as
previously described [13]. Mass spectra were acquired on a
Ultraflex MALDI TOF-TOF mass spectrometer (Bruker Dal-
Figure 1. Comparison of Shigella sonnei GMMA from different strains and different conditions. A)25 ml of culture supernatants were
collected from (1) wild type S. sonnei 53G, (2) S. sonnei DtolR (3) S. sonnei DtolR DgalU, (4) S. sonnei –pSS DtolR, and (5) S. sonnei –pSS DtolR DmsbB
grown in flasks in chemically defined medium at 30uC. Proteins were precipitated from the supernatants and quantified using Bradford assay. 10 mg
of samples 2–5, respectively, and the total quantity of sample 1 obtained from 25 mL of supernatant were separated by SDS-PAGE (12%
polyacrylamide (PA)). All strains with deletion of the tolR gene show an extensive protein profile in the supernatant compared to wild type. B) GMMA
were purified by ultracentrifugation from flask cultures of S. sonnei –pSS DtolR grown in chemically defined medium with 100 mM iron at 37uC and
30uC. 10 mg of protein were separated by SDS-PAGE (12% PA). The protein pattern of GMMA obtained at the different temperatures is similar. Visible
differences are marked by arrows. C) S. sonnei 53G –pSS DtolR was grown in flasks in chemically defined medium with defined iron concentrations.
GMMA were purified by ultracentrifugation and GMMA proteins were separated by SDS-PAGE (4–12% PA). Three bands identified as FepA, IutA, and
colicin I receptor were shown to be repressed by high iron concentration. D) Densitometry analysis of GMMA preparation from strain S. sonnei DtolR
DgalU grown in a 5 L fermenter to OD 45. The most abundant proteins were identified by protein mass fingerprint and relative amounts were
determined by densitometry analysis. Of the highlighted proteins, all proteins with exception of TolB are predicted to be associated with the outer
membrane, indicating that approximately 69% of the total protein amount in GMMA is derived from abundant proteins linked to the outer
membrane.
doi:10.1371/journal.pone.0035616.g001
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3,500 Da. Spectra were externally calibrated by using a combi-
nation of standards pre-spotted on the target (Bruker Daltonics).
MS spectra were analyzed by Protein Mass Fingerprint (PMF)
with flexAnalysis (flexAnalysis version 2.4, Bruker Daltonics).
Monoisotopic peaks were annotated with flexAnalysis default
parameters and manually revised. Protein identification was
carried from the generated peak list using the Mascot program
(Mascot server version 2.2.01, Matrix Science). Mascot was run on
a database containing protein sequences deduced from seven
sequenced Shigella genomes, downloaded from NCBInr or from
the Wellcome Trust Sanger Institute database. Genomes used
were from strains Shigella sonnei 53G, Shigella flexneri 2a str. 301,
Shigella flexneri 2a str. 2457T, Shigella sonnei Ss046, Shigella boydii
Sb227, Shigella flexneri 5 str. 8401, Shigella boydii CDC 3083-94.
Search parameters, mass tolerance, known contaminant ions,
validation and handling of multiple matches were performed as
described previously [13].
Protein Precipitation and In-solution Protein Digestion
Proteins from supernatants or purified GMMA were precipi-
tated by adding TCA and deoxycholate to a final concentration of
10% and 0.04%, respectively. The precipitation was allowed to
proceed for 30 min at 4uC. The precipitate was recovered by
10 min centrifugation at 20,0006ga t4 uC. The pellet was washed
once with 10% TCA (wt/vol) and twice with absolute ethanol,
dried with Speedvac (Labconco, Kansas City, U.S.A). For analysis
by SDS-PAGE, the precipitates were resuspended with 200 mM
Tris-HCl, pH 8.8, and quantified. For LC-MS/MS analysis 20 mg
of GMMA were precipitated and resuspended in 50 mL, 6 M
guanidinium chloride, 5 mM DTT, 200 mM Tris-HCl, pH 8.0.
Denaturation proceeded for 60 min at 60uC. Prior to digestion,
the solution was diluted 1:8 with a solution of 100 mM Tris-HCl,
pH 8.0, 5 mM DTT and 5 mg of trypsin (Promega) were added to
the diluted solution. Digestion was carried out over night at 37uC.
The reaction was stopped by adding formic acid to 0.1%. Peptides
were extracted using Oasis extraction cartridges (HLB 1cc (30 mg)
extraction cartridges, Waters, Milford, MA, USA) and analyzed by
LC-MS/MS.
Protein Identification by Nano-LC-MS/MS
Peptides were separated by nano-LC on a NanoAcquity UPLC
system (Waters) connected to a Q-ToF Premier ESI mass
spectrometer equipped with a nanospray source (Waters). Samples
were loaded onto a NanoAcquity 1.7 mm BEH130 C18 column
(75 mm625 mm; Waters) through a NanoAcquity 5 mm Symme-
try C18 trap column (180 mm620 mm; Waters). Peptides were
eluted with a 120 min gradient of 2–40% acetonitrile (98%), 0.1%
formic acid solution at a flow rate of 250 nL/min. The eluted
peptides were subjected to an automated data-dependent acqui-
sition using the MassLynx software, version 4.1 (Waters) where an
MS survey scan was used to automatically select multicharged
peptides over the m/z ratio range of 300–2000 for further MS/
MS fragmentation. Up to eight different peptides were individually
subjected to MS/MS fragmentation following each MS survey
scan. After data acquisition, individual MS/MS spectra were
combined, smoothed, and centroided using ProteinLynx, version
3.5 (Waters) to obtain the peak list file. The Mascot Daemon
application (Matrix Science Ltd., London, UK) was used for the
automatic submission of data files to in-house licensed Mascot,
version 2.2.1, running on a local server. The Mascot search
parameters were set to (i) 2 as the number of allowed missed
cleavages (only for trypsin digestion), (ii) methionine oxidation as
variable modifications, (iii) 0.05 Da as the peptide tolerance, and
(iv) 0.05 Da as the MS/MS tolerance. Only significant hits were
considered as defined by the Mascot scoring and probability
system.
Bioinformatics
Prediction of protein localization was carried out using
PSORTb v3.0 [34] and Lipo program [35].
Mouse Immunizations
Outbred CD1 mice (female, 4 to 6 weeks of age) received
three injections of GMMA via the subcutaneous route on days 0,
21, and 35. Each injection contained GMMA normalized to
0.2 mgo r2 mg of protein and formulated in PBS only, with
Freund’s adjuvant (FA), or adsorbed onto aluminum hydroxide
(alum), 2 mg/mL, in a final volume of 100 mL. If Freund’s
adjuvant was used, Freund’s complete adjuvant (FCA) was used
for the first immunization, Freund’s incomplete adjuvant (ICFA)
was used for the second and third immunization. Control mice
received either adjuvant or PBS alone. Blood samples were
collected before immunization and 14 days after the second and
third injection. The animal experiments complied with the
relevant guidelines of Italy and the institutional policies of
Novartis. The animal protocol was approved by the Animal
Welfare Body of Novartis Vaccines and Diagnostics, Siena, Italy,
approval number AEC 2009-05.
Western Blot
GMMA were boiled in loading buffer and loaded on 12% (wt/
vol) polyacrylamide-SDS gels (BioRad) or on 2D gels as described.
Gels were run in MOPS buffer (BioRad) and protein were
subsequently transferred onto nitrocellulose membrane using
Trans-blot transfer medium (BioRad). The membranes were
blocked in PBS containing 3% (wt/vol) powdered milk, then
incubated with mouse polyclonal antisera diluted (1:1000) in PBS
containing 3% (wt/vol) milk for 90 min at 37uC. Membranes were
washed three times with PBS containing Tween 20, 0.1% (vol/vol)
and then incubated with sheep anti-mouse horseradish peroxidase-
conjugated IgG (GE Healthcare, UK Limited), diluted (1:7500) in
PBS containing 3% (wt/vol) milk. Colorimetric staining was
performed, after washing the membranes, with SuperSignal West
Pico Chemiluminescent Substrate Kit (Pierce, Rockford, U.S.A.)
as described by the manufacturer. Positive signals were related to
the corresponding proteins by comparing the Western blot
membrane to the gel using Ponceau staining of the membrane
as a reference and aligning the images with Image master 2D
Platinum 6.0.
Enzyme-linked Immunosorbent Assay (ELISA)
To measure Shigella sonnei GMMA-specific immunoglobulin G
(IgG) in mice serum, Nunc Maxisorb 96-well plates were coated
over night at 2 to 8uC with 100 mL/well of a 0.5 mg/mL
suspension of Shigella sonnei 53G –pSS DtolR GMMA, purified from
defined medium with 2 mM ferric citrate in the same way as the
GMMA in the vaccine, diluted in phosphate-buffered saline (PBS).
Plates were then washed three times with 300 mL/well of
phosphate-buffered saline containing 0.05% (vol/vol) Tween 20
(PBST) and blocked with PBS containing 1% (wt/vol) BSA for
60 min at 37uC. Serial dilutions of reference and sample sera were
prepared in PBST, 1% (wt/vol) BSA in a separate dilution plate,
and 100 mL/well of each serial dilution was transferred to the
coated plate, incubated for 2 hours at 37uC, and then washed as
described above. Bound antibody was detected using a goat anti-
mouse IgG conjugated to alkaline phosphatase, diluted in PBST,
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AB C DE
Outer membrane
1 3 outer membrane channel protein [S. flexneri 2a str. 301] tolC gi|56480244
2 3 outer membrane porin protein C [S. sonnei Ss046] ompC gi|74312736
3 3 outer membrane protein A [S. sonnei Ss046] ompA gi|74311514
4 3 outer membrane protein induced after carbon starvation [S. flexneri 5 str. 8401] slp gi|110616891
5 3 outer membrane protein X [S. flexneri 2a str. 301] ompX gi|56479734
6 2 outer membrane protein assembly factor YaeT [S. Flexneri 2a str. 301] yaeT gi|24111612
7 2 outer membrane protein C [S. boydii CDC 3083-94] ompC gi|187733369
8 2 outer membrane receptor FepA [Shigella sonnei Ss046] fepA gi|74311118
9 2 ferrichrome outer membrane transporter [Shigella sonnei Ss046] fhuA gi|74310771
10 2 colicin I receptor [Shigella sonnei Ss046] cirA gi|74312677
11 2 maltoporin [Shigella flexneri 2a str. 301] lamB gi|56480532
12 4 putative ferric siderophore receptor [S. sonnei Ss046] iutA gi|74313972
13 2 outer membrane protein W [Shigella sonnei Ss046] yciD gi|74312394
14 2 serine protease [S. flexneri 2a str. 301] sigA gi|24114232
Outer membrane Lipoproteins
15 3 murein lipoprotein [S. flexneri 2a str. 301] lpp gi|24113066
16 2 outer membrane lipoprotein LolB [S. flexneri 2a str. 301] lolB gi|24112608
17 3 peptidoglycan-associated outer membrane lipoprotein [S. flexneri 2a str. 301] pal gi|56479690
18 1 entericidin B membrane lipoprotein [S. flexneri 2a str. 301] ecnB gi|24115506
19 1 hypothetical protein S2067 [S. flexneri 2a str. 2457T] yedD gi|30063370
20 1 hypothetical protein S4565 [S. flexneri 2a str. 2457T] yjeI gi|30065519
21 1 hypothetical protein SF0398 [S. flexneri 2a str. 301] ybaY gi|24111837
22 1 RpoE-regulated lipoprotein [S. flexneri 2a str. 301] SF2485 gi|24113773
23 1 hypothetical protein SSON_2966 [S. sonnei Ss046] SSON_2966 gi|74313380
24 1 lipoprotein [S. flexneri 2a str. 2457T] nlpB gi|30063856
25 2 entry exclusion protein 2 [S. sonnei Ss046] exc gi|145294038
26 2 LPS-assembly lipoprotein RplB [S. dysenteriae Sd197] rplB gi|82775909
27 2 putative pectinesterase [S. sonnei Ss046] ybhC gi|74311310
28 4 outer membrane protein assembly complex subunit YfiO [Shigella sonnei Ss046] SSON_2721 gi|74313154
29 3 outer membrane lipoprotein [S. flexneri 2a str. 301] yraP gi|24114441
30 3 DNA-binding transcriptional activator OsmE [S. flexneri 2a str. 301] lipo osmE gi|24112862
31 1 outer membrane protein [S. flexneri 2a str. 301] slyB gi|24113033
Periplasmic
32 3 FKBP-type peptidyl-prolyl cis-trans isomerase [S. Flexneri 2a str. 301] fkpA gi|24114611
33 3 histidine-binding periplasmic protein of high-affinity histidine transport system [S. sonnei Ss046] hisJ gi|74312826
34 3 serine endoprotease [S. flexneri 2a str. 301] htrA gi|24111599
35 3 translocation protein TolB [S. flexneri 2a str. 2457T] tolB gi|30062097
36 1 molybdate transporter periplasmic protein [S. flexneri 2a str. 301] modA gi|24111968
37 1 peptidyl-prolyl cis-trans isomerase A (rotamase A) [S. flexneri 2a str. 301] ppiA gi|24114628
38 1 peptidyl-prolyl cis-trans isomerase SurA [S. flexneri 2a str. 301] surA gi|24111499
39 1 periplasmic oligopeptide binding protein [S. flexneri 2a str. 2457T] oppA gi|30062764
40 1 periplasmic protein [S. flexneri 2a str. 2457T] osmY gi|30065614
41 2 arginine 3rd transport system periplasmic binding protein [S. sonnei Ss046] artJ gi|74311404
42 2 bifunctional UDP-sugar hydrolase/59-nucleotidase [S. sonnei Ss046] ushA gi|74311061
43 2 cystine transporter subunit [S. sonnei Ss046] fliY gi|74311733
44 2 glucan biosynthesis protein G [S. flexneri 5 str. 8401] mdoG gi|110805056
45 2 thiosulfate transporter subunit [S. sonnei Ss046] cysP gi|74312961
46 2 hypothetical protein SBO_2040 [Shigella boydii Sb227] ycdO gi|82544504
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After a wash with PBST, 100 mL/well of p-nitrophenyl phosphate
substrate dissolved in diethanolamine buffer (1 M, pH 9.8) was
added, and after 20 minutes optical densities were measured with
a plate reader (ELx800, BioTek) at 405 and 490 nm wavelength.
Absorbance at 490 nm was subtracted from the absorbance at
405 nm. Results are expressed in arbitrary ELISA units relative to
a standard serum raised against GMMA from S. sonnei 53G DtolR
DgalU. One unit equals the reciprocal of the dilution of the
standard serum giving an OD405–490 of 1 in the assay. All samples
were measured in duplicate.
Statistical Analysis
Antibody levels (ELISA units) in different groups after the third
immunization were compared by non-parametric Kruskal-Wallis
and Mann-Whitney tests. A p value of 0.05 was considered to be
significant. For multiple comparisons the p value considered to be
significant in each of the comparisons was adjusted according to
the number of analyses.
Results
Generation of a Shigella Sonnei 53G Strain Capable of
Overproducing Modified GMMA
The first aim of the study was to investigate if Shigella sonnei 53G
could be developed as a strain suitable to overproduce GMMA
through modification of the Tol-Pal system. A null mutation of the
tolR gene was introduced as this has previously been demonstrated
to result in overproduction of GMMA in E. coli [11,13]. The
mutation in the tolR gene led to the release of large amounts of
GMMA from the surface of S. sonnei 53G as assessed by SDS page
(Fig. 1A). The deletion of tolR had no detectable influence on
bacterial growth (data not shown). In addition, to test if GMMA
overproduction is also feasible in strains with additional genetic
modifications we removed the O antigen of the LPS, either by
deletion of galU [26] or by curing the virulence plasmid from strain
S. sonnei 53G DtolR as the biosynthesis genes for the O antigen in
Shigella sonnei are encoded on the plasmid [36]. GMMA obtained
from S. sonnei DtolR DgalU showed a similar protein profile to
GMMA obtained from S. sonnei DtolR with minor differences in the
37 kDa to 50 kDa range and proteins smaller than 30 kDa
appeared to be less abundant in S. sonnei DtolR DgalU (Fig. 1A).
Also GMMA obtained from the plasmid-cured S. sonnei DtolR
mutant (S. sonnei –pSS DtolR) showed a nearly identical protein
pattern to GMMA from S. sonnei DtolR (Fig. 1A).
Furthermore, the genes msbB1 and msbB2 involved in lipid A
biosynthesis were deleted since these deletions have previously
been reported to decrease LPS toxicity in Shigella [21]. As the gene
msbB2 is encoded on the virulence plasmid and thus absent in
S. sonnei –pSS DtolR we deleted the chromosomal gene msbB1 in
this strain to generate a mutant strain lacking msbB1 and msbB2.
For simplicity the DmsbB1DmsbB2 mutant is referred to as the
DmsbB mutant. The DmsbB mutant was selected at 37uCo nL B
plates and grew in LB and yeast extract at 37uC with a duplication
time of about 55 min compared to a duplication time of about
28 min for the single DtolR mutant. In the defined medium
developed for fermentation, the plasmid-cured DtolR DmsbB
mutant strain (S. sonnei –pSS DtolR DmsbB) was able to grow to
high optical density (OD) at 30uC, but grew poorly at 37uC. Thus,
Table 2. Cont.
AB C DE
47 2 hypothetical protein SFV_2968 [S. flexneri 5 str. 8401] yggE gi|110806822
Cytoplasmic
48 3 chaperonin GroEL [S. flexneri 2a str. 301] groEL gi|24115498
49 3 dihydrolipoamide dehydrogenase [S. flexneri 2a str. 301] lpdA gi|56479605
50 1 purine nucleoside phosphorylase [S. flexneri 2a str. 2457T] deoD gi|30065622
51 1 succinyl-CoA synthetase subunit beta [S. flexneri 2a str. 301] sucC gi|24111996
52 2 PTS system glucose-specific transporter subunit [S. flexneri 2a str. 301] crr gi|24113762
53 2 molecular chaperone DnaK [S. flexneri 2a str. 301] dnaK gi|24111463
54 1 pyrroline-5-carboxylate reductase [S. flexneri 2a str. 301] proC gi|24111764
55 2 hypothetical protein SF1022 [S. flexneri 2a str. 301] SF1022 gi|24112431
Inner membrane
56 1 hypothetical protein SSON_1546 [S. sonnei Ss046] ydgA gi|74312061
Unknown
57 3 putative receptor [S. sonnei Ss046] SSON_1681 gi|74312191
58 2 hypothetical protein SSON_1556 [S. sonnei Ss046] ydgH gi|74312071
59 2 hypothetical protein SSON_3340 [S.sonnei Ss046] yrbC gi|74313729
60 2 putative lipoprotein [Shigella dysenteriae Sd197] ybjP gi|82777619
61 1 hypothetical protein S3269 [S. flexneri 2a str. 2457T] ygiW gi|30064374
GMMA were purified by 2-step TFF from S. sonnei DtolR DgalU grown in HTMC at 37uC to an OD of 45. GMMA-associated proteins were separated by SDS-PAGE or nano-
LC and identified by mass spectrometry. 61 GMMA-associated proteins were identified. The columns show: A) position in list, B) method used to identify each protein
(‘19: identified from total digestion LC/MS-MS, ‘29: identified from 2D SDS-PAGE PMF, ‘39 identified from LC/MS-MS and 2D SDS-PAGE PMF, ‘49 identified from 1D SDS-
PAGE PMF), C) annotation, D) gene name, E) accession number. The entries are divided by predicted location. All proteins were analyzed by PSORTb 3.0 and Lipo. If a
prediction as lipoprotein was obtained, the protein is listed as lipoprotein irrespective of its PSORTb prediction. Only lipoproteins predicted to be located in the outer
membrane have been identified. The other proteins are listed in sections corresponding to their location predicted by PSORTb. For 5 proteins no prediction was
obtained by PSORTb or Lipo. These are listed as ‘unknown’.
doi:10.1371/journal.pone.0035616.t002
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cultivation in chemically defined medium at a growth temperature
of 30uC was chosen. GMMA from S. sonnei –pSS DtolR DmsbB
produced under these conditions showed a similar protein pattern
to GMMA generated by S. sonnei –pSS DtolR and S. sonnei DtolR
with only minor variation in relative amounts of proteins visible by
SDS-PAGE in the 45–75 kDa range (Fig. 1A). In order to test if
the lower temperature would change the GMMA composition we
compared GMMA derived from S. sonnei –pSS DtolR at 30uCo r
37uC. Only few differences were detected as highlighted in Fig. 1B,
indicating that GMMA can be generated at 30uC without major
effects on the composition. In conclusion, deletion of tolR greatly
enhanced GMMA release while additional genetic modification of
the strain or a change in growth temperature only had minor
effects on the protein composition visible by SDS-PAGE.
High Density Cultivation of Shigella Sonnei
To investigate the feasibility to produce GMMA at large scale,
S. sonnei 53G DtolR DgalU, S. sonnei 53G –pSS DtolR, and S. sonnei
53G –pSS DtolR DmsbB were tested for their capacity to grow to
high densities in a 5 liter reactor. Starter cultures were grown in
flasks to OD 0.8 and were then transferred to the 5 L fermenter
to reach a starting OD of 0.02. Dissolved oxygen was maintained
at 30% saturation. The pH was maintained at 7.2 in HTMC or
at 6.7 in SSDM and the temperature was kept constant either at
37uCo ra t3 0 uC when S. sonnei 53G –pSS DtolR DmsbB was used.
Under these conditions, cultures with optical densities of 45 to 80
were obtained.
Iron-regulated proteins have previously been shown to be
important in vaccine formulations against Pasteurella and Salmonella
[37,38]. Thus, we evaluated if the GMMA process would allow the
upregulation of iron-regulated proteins. Growth of S. sonnei 53G –
pSS DtolR with 0.2 mM iron concentration in chemically defined
medium led to the induction of iron-regulated proteins but
hindered high density cultivation of bacteria. The addition of
2 mM iron to the medium was sufficient to allow optimal growth
and the induction of three iron-regulated proteins visible by SDS-
PAGE (Fig. 1C), identified by protein mass fingerprint as FepA
(gi|74311118), IutA (gi|74313972) and Colicin I receptor
(gi|74312677). The expression of these proteins was reduced
when bacteria were grown in 200 mM iron (Fig. 1C). In bacteria
grown in HTMC the iron-regulated proteins are expressed to a
similar level as in chemically defined medium with 200 mM iron
(data not shown). Their presence was confirmed by protein mass
fingerprint analysis of GMMA generated from S. sonnei DtolR
DgalU grown in HTMC (Table 2, proteins 8, 10, 12). Growth of
S. sonnei 53G –pSS DtolR DmsbB at 30uC in defined medium with
2 mM iron also enhanced expression of FepA and IutA. Colicin I
receptor (marked in Fig. 1C) was less expressed than in GMMA
from S. sonnei 53G –pSS DtolR prepared from cultures grown at
37uC (data not shown).
Purification of GMMA from High Density Culture
Supernatant
So far, GMMA have always been purified from flask cultures by
ultracentrifugation [13]. Cultures were centrifuged at low speed
(4000 g) to separate biomass from supernatant which was
subsequently filtered through a 0.22 mm filter. GMMA present
in the supernatant were collected by ultracentrifugation, washed,
and then resuspended and stored in PBS [10,13]. Since this
technique is not suitable for large volumes we developed a scalable
purification method to purify GMMA from high density cultures
using tangential flow filtration (TFF). In TFF, also known as
crossflow filtration, the feed stream is pumped tangentially across
the surface of the membrane rather than into the filter as in
conventional ‘dead-end’ filtration. A proportion of the soluble
components and particles smaller than the membrane’s pores
penetrates the filter (filtrate/permeate). The remainder (retentate)
is circulated back to the reservoir and over the filter again. In this
way, the larger particles do not build up at the surface of the filter
but are swept away by the tangential flow allowing smaller
molecules to continuously reach and pass through the membrane.
This feature makes TFF an efficient process for size separation,
concentration and diafiltration.
Figure 2. GMMA enrichment and purity after TFF. GMMA were
purified from a 5 L fermentation culture of S. sonnei DtolR DgalU grown
in HTMC at 37uC to OD 45 using 2-step TFF. In the first step, the culture
supernatant which contains the GMMA was separated from the bacteria
using a 0.2 mm filter. The biomass was subjected to 5 diafiltration steps
and all filtrates were combined with the initial supernatant to obtain
the total permeate. To determine the amount of GMMA in the
permeate, GMMA were separated from soluble proteins by ultracentri-
fugation. After ultracentrifugation, the pellet (GMMA) was resuspended
in the initial volume of the centrifuged material to normalize all samples
to fermentation volume. Equivalent volumes of the 0.2 mm filtrate
before ultracentrifugation (1), the resuspended GMMA pellet (2), and
the supernatant of the ultracentrifugation (3) were separated by SDS-
PAGE (12% PA) and showed a large amount of soluble proteins (3) in
comparison to GMMA-associated proteins (2) to be present in the post
0.2 mm TFF permeate. In the second TFF step, GMMA were separated
from soluble proteins using a 0.1 mm filter. The retentate (4) was
analyzed by ultracentrifugation as described above and was found to
contain almost exclusively GMMA (5) as determined by the strong
reduction of soluble proteins (6).
doi:10.1371/journal.pone.0035616.g002
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TFF process. In the first step, the culture supernatant that contains
the GMMA was separated from the bacteria using a 0.2 mm filter.
In this step, the bacteria remained in the retentate and GMMA
transferred into the filtrate. In the second filtration step using a
0.1 mm filter, GMMA were separated from soluble components
present in the culture supernatant, including proteins secreted by
the bacteria or released by lysis. In this step, GMMA were retained
by the filter and collected and concentrated in the retentate
whereas soluble proteins passed through the filter. We tested this
purification process under two slightly different conditions. Firstly,
when the fermentation culture of S. sonnei DtolR DgalU reached OD
45, the culture was transferred directly from the fermenter to the
first TFF and the culture supernatant containing the GMMA was
collected. The retained biomass was washed with 5 volumes of
PBS buffer (diafiltration) to recover remaining GMMA and the
filtrate containing these GMMA was combined with the culture
supernatant. In the slightly modified purification process tested,
this diafiltration step was omitted. Proteins were quantified by
Bradford method. In the purification performed with diafiltration
of the biomass the total protein content of the TFF 0.2 mm filtrate
was approximately 1.5 g/L of fermentation culture of which 15%
was GMMA-associated as determined by separation of the soluble
components from the high molecular weight portion (GMMA) via
an ultracentrifuge step (Fig. 2 and Table 3). In the second TFF
step, GMMA were concentrated in the retentate and washed with
five volumes of PBS to remove remaining soluble proteins. As TFF
is usually performed under non-sterile conditions, the final
retentate was sterilized by filtration through a 0.22 mm filter. An
aliquot of the sterilized retentate was subjected to ultracentrifu-
gation to determine the content of GMMA as above. As shown in
Fig. 2 most of the proteins in the retentate are GMMA-associated.
Protein quantification of the retentate, of the GMMA fraction, and
of the supernatant of the ultracentrifugation step (soluble proteins)
determined that 90% of all protein present in the retentate was
GMMA-associated (Table 3). Thus, soluble proteins were
efficiently removed in this step (Fig. 2). GMMA recovery after
the 0.1 mm TFF step was 56% of the quantity present after the
0.2 mm cassette. The final yield of GMMA was 120 milligrams of
proteins per liter of fermentation (Table 3). In two subsequent tests
of the purification method with S. sonnei DtolR DgalU without
diafiltration of the biomass, a lower amount of GMMA was
obtained in the 0.2 mm TFF filtrate (Table 3). However, recovery
of GMMA in the second TFF step (0.1 mm) was enhanced
resulting in an overall similar yield of GMMA with equivalent
purity (Table 3 and suppl. figures Fig. S1, Fig. S2). This suggests,
firstly, that washing of the biomass increases the recovery GMMA
from the fermentation culture, and secondly, that a higher starting
concentration might be beneficial for the second TFF step. The
0.1 mm TFF step can likely be optimized to take advantage of the
larger amounts of GMMA obtained by diafiltration of the biomass.
Fermentations of S. sonnei –pSS DtolR DmsbB resulted in yields of
140 mg/L from a culture at OD 65 (2.2 mg/L/OD) and 230 mg/
L from a culture at OD 80 (2.9 mg/L/OD), demonstrating that
the yield of GMMA can be further improved by growing the
culture to a higher OD.
The preparation of GMMA generated from S. sonnei –pSS DtolR
DmsbB obtained after the second TFF step was subjected to
electron microscopy analysis, revealing the presence of well-
organized membrane vesicles with a diameter of about 30–60 nm
(Fig. 3) which is consistent with the reported average size of
Table 3. Yield, purity, and recovery rate of GMMA by the high yield production process.
Fermentation A OD 45 Fermentation B1 OD 30 Fermentation B2 OD 39
Protein content [mg/L fermentation]
0.2 mm TFF permeate
Total protein* 1465 1237 797
GMMA-associated protein 214 143 138
Soluble protein 1251 1094 659
0.1 mm TFF retentate
Total protein
# 108 144 118
GMMA-associated protein 120 127 114
Soluble protein 14 5 3
GMMA-associated protein per OD 2.7 mg/L/OD 4.2 mg/L/OD 2.9 mg/L/OD
Purity of GMMA after 0.1 mm TFF [%]
GMMA (GMMA-protein/total protein) 90 88 97
Soluble protein (sol. protein/total protein) 10 3 3
Recovery of GMMA by 0.1 mm TFF [%]
GMMA-protein after 0.1 mm TFF/0.2 mm5 6 8 9 8 3
*Total protein amount calculated as sum of GMMA-associated protein and soluble protein.
#Total protein amount measured directly by Bradford assay.
S. sonnei DtolR DgalU was grown in HTMC in a 5 L fermenter to high densities of OD 45 (A), OD 30 (B1) and OD 39 (B2) and GMMA were purified using 2-step TFF.
Purification from fermentation A was performed including 5 diafiltration steps of the biomass, for GMMA purification from fermentations B1 and B2 the biomass was not
subjected to diafiltration. The GMMA content in the permeate of the 0.2 TFF step (culture supernatant) and the retentate of the 0.1 mm TFF (purified GMMA) were
determined by separation of GMMA from soluble protein by ultracentrifugation. Protein was quantified using Bradford assay. All samples were normalized to amount
per liter fermentation broth. To compare the yields from different ODs, yields are also expressed as amount per liter fermentation per OD.
doi:10.1371/journal.pone.0035616.t003
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mutants [11].
Characterization of GMMA Protein Content
GMMA purified by TFF from S. sonnei 53G DtolR DgalU grown
in high density culture were characterized to confirm their
integrity and to analyze their protein content. One- and two-
dimensional SDS-PAGE of GMMA and densitometry analysis
(Fig. 1D and Fig. 4) were used to determine the protein profile and
to study relative protein quantities of the most abundant proteins.
Most of the Coomassie blue-stained bands and spots were
identified using peptide mass fingerprint (Table 2). OmpA and
OmpC are known to be among the most abundant proteins
present in the outer membrane. In fact, densitometry analysis of
GMMA from S. sonnei DtolR DgalU grown in HTMC and analyzed
by 1D SDS-PAGE indicated that OmpA and OmpC together
contribute for 45% of the total protein; OmpX, 9%; Slp, 6%;
YfiO, 5.6%; TolB, 2.3%; TolC 1.4%; and YaeT, 1.8% (Fig. 1D).
With the exception of the predicted periplasmic protein TolB, all
of these proteins are predicted to be associated with the outer
membrane. YfiO is predicted to be an outer membrane
lipoprotein. OmpA, OmpC, OmpX, Slp, TolC, and YaeT are
predicted to be outer membrane proteins. Thus, the seven most
abundant outer membrane-associated proteins account for
approximately 69% of the protein amount in GMMA. Further
densitometry analysis after 2D SDS-PAGE determined that there
are approximately equal quantities of OmpA and OmpC
(OmpA:OmpC is 1:0.83 by densitometry of a Coomassie blue-
stained gel). In order to identify the diverse and less expressed
proteins, GMMA were studied by proteolytic digestion and reverse
Figure 3. Electron microscopy of Shigella sonnei DtolR DgalU GMMA. GMMA were isolated from the culture supernatant of S. sonnei –pSS
DtolR DmsbB by TFF, prepared for negative staining, and viewed by electron microscopy revealing the presence of well-organized membrane vesicles
with a diameter of about 30–60 nm. Bar length =100 nm.
doi:10.1371/journal.pone.0035616.g003
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were identified in total (LC-MS/MS, 1D and 2D SDS-PAGE
PMF) (Table 2), with 31 of these proteins predicted to be
associated with the outer membrane (Fig. 5). Of these, 14 proteins
were predicted to be outer membrane proteins and 17 to be outer
membrane lipoproteins. In addition, 16 proteins were predicted to
be periplasmic, 8 to be cytoplasmic, 1 to be located in the inner
membrane, and for 5 proteins no prediction could be obtained. No
inner membrane lipoproteins were predicted. Thus, GMMA
generated by the high yield production process are mostly
composed of outer membrane-associated and periplasmic proteins
as previously seen for outer membrane particles release from
cultures at the early logarithmic phase [10,13].
GMMA Immunogenicity
Groups of 8 CD1 mice were immunized 3 times with GMMA
(2 mg of total protein) obtained from S. sonnei 53G –pSS DtolR and
S. sonnei 53G –pSS DtolR DmsbB, both grown in defined medium
with 2 mM iron, and S. sonnei 53G DtolR DgalU grown in HTMC.
GMMA from S. sonnei 53G –pSS DtolR DgalU, S. sonnei 53G –pSS
DtolR and S. sonnei 53G –pSS DtolR DmsbB were also administered
in combination with Freund’s adjuvant (FA). Freund’s complete
adjuvant was used in the first immunization and Freund’s
incomplete adjuvant was used in the second and third immuni-
zation. In addition, a lower dosage of 0.2 mg of GMMA from
S. sonnei 53G –pSS DtolR DmsbB was tested. Serum samples were
obtained 2 weeks after the second and third doses and analyzed
individually. Mice immunized with GMMA showed very high IgG
responses to all 3 types of GMMA that were tested. No difference
was found between groups immunized with different GMMA or
between groups receiving the same GMMA with or without FA
(Fig. 6). Adsorption of GMMA onto alum as adjuvant also did not
have an effect on the IgG response (data not shown). Control mice
immunized with PBS or FA alone had very low levels of anti-
GMMA antibodies (Fig. 6). The 10-fold lower dosage of GMMA
from S. sonnei 53G –pSS DtolR DmsbB (0.2 mg) resulted in a
statistically significant, approximately 3-fold reduction in the IgG
response compared to the group immunized with 2 mg of the same
GMMA. However, the IgG response to the lower dosage still
showed an approximately 8000-fold increase compared to
preimmune sera (Fig. 6).
To investigate which components of GMMA were responsible
for the reactivity of the sera, 2D Western blots were performed. As
GMMA from S. sonnei 53G DtolR DgalU were characterized best in
respect to their protein content, sera from mice immunized with
the GMMA from S. sonnei DtolR DgalU were used to probe blots of
2D SDS-PAGE of GMMA from the same strain. Reactive
proteins were identified by protein mass fingerprint. Several
proteins were detected by the sera (Fig. 4 B) of which OmpA gave
the strongest response. OmpC which is as abundant in GMMA as
OmpA was not detected. Not all of the visible reactive proteins
could be identified.
Discussion
Recent advances in genomics and reverse vaccinology have
identified promising protein targets for vaccines [39]. In many
cases, suitable candidate antigens for Gram-negative bacterial
vaccines are outer membrane proteins and these pose particular
challenges in their expression and purification and in serotype
variability. An ideal delivery system especially for bacterial
vaccines for developing countries will encompass multiple antigens
and enable vaccines to be rapidly tailored to local and changing
antigenic serotypes. Ideally, it will also be inexpensive to
manufacture. We propose a platform for rapid development and
delivery of vaccines against Gram-negative bacteria. The ap-
proach is based on the production of outer membrane particles we
have named GMMA by genetically modified bacteria. Using
genetic manipulation, it is possible to increase their yield, to
remove immunodominant structures, to overexpress certain
Figure 4. 2D gel electrophoresis of Shigella sonnei DtolR DgalU GMMA and immunoblot. A)200 mg of proteins from S. sonnei DtolR DgalU
GMMA were separated in the first dimension on a non linear pH 3–11 gradient, and in the second dimension on a 4–12% polyacrylamide gradient.
Visible bands were identified by protein mass fingerprint. OmpA and OmpC were quantified with Image master 2D Platinum 6.0. B) Sera from mice
immunized with GMMA from S. sonnei DtolR DgalU were used to study the subset of proteins present in GMMA that are able to raise antibodies. A 2D
gel containing 20 mg of GMMA protein from S. sonnei DtolR DgalU was blotted and the membrane was incubated with sera from immunized mice
with GMMA from S. sonnei DtolR DgalU in combination with Freund’s adjuvant. Several reactive proteins were identified. The numbers behind the
names refer to the position of the proteins in Table 2. C) To verify that the signal observed in the 2D Western blot was due exclusively to antibody
raised upon immunization with GMMA, 10 mg of GMMA were separated by 1D SDS-PAGE (12% PA) and stained with Coomassie (1) or transferred to a
membrane. Western blots were developed using (2) sera raised against GMMA from S. sonnei DtolR DgalU as used for the 2D Western blot in B, (3)
preimmune serum, (4) sera raised in mice immunized with Freund’s adjuvant or (5) PBS, or (6) secondary antibody only. A signal could only be
observed when sera raised against GMMA were used (2).
doi:10.1371/journal.pone.0035616.g004
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[10,13,19,21,26,40,41]. GMMA could potentially be a safe,
effective and low cost vaccine but need a practical way of
manufacture at scale.
Shigella sonnei 53G was chosen for a first approach to develop a
scalable process and a null mutation of the tolR gene was
introduced to overproduce GMMA as previously described for E.
coli [13]. To verify that the process is applicable to produce
GMMA harboring modified lipid A, which would be more suitable
for use as vaccine, and/or lacking the O antigen of the LPS we
grew high density cultures of S. sonnei DtolR DgalU, S. sonnei –pSS
DtolR (cured of the virulence plasmid pSS), and S. sonnei –pSS
DtolR DmsbB in a 5 L fermenter in complex (HTMC) or
chemically defined medium. Chemically defined medium was
used to avoid contamination from proteins present in complex
media and to have the possibility to regulate iron concentration.
Bacteria were removed from the culture supernatant by a
tangential flow filtration step using a 0.2 mm membrane. A second
tangential flow filtration step with a 0.1 mm membrane was used to
concentrate GMMA and to remove soluble proteins. This choice
of appropriate molecular weight membranes allowed the purifi-
cation of GMMA in an easy, efficient, and scalable process. After
purification, approximately 90% of all protein was consistently
GMMA-associated with reproducible yields of more than 100 mg
of GMMA-associated protein per liter fermentation volume from
OD 30–45 cultures of S. sonnei DtolR DgalU. The integrity of
GMMA obtained by this process was confirmed using electron
microscopy. The purity and yield can likely be increased as
indicated by fermentations with S. sonnei –pSS DtolR DmsbB to
densities of 65 and 80. Furthermore, first results obtained by
quantitative amino acid analysis of different types of GMMA
indicated an at least two-fold higher protein amount in the
GMMA preparations than determined by the Bradford assay used
in this study (data not shown). Still, assuming an average yield of
100 mg/L fermentation and a dosage of 25 mg as used for the
MeNZB outer membrane vesicle meningococcal vaccine, at least
400,000 doses could be obtained from a 100 L fermenter.
A proteomic approach confirmed that Shigella sonnei 53G DtolR
DgalU-derived GMMA are composed mostly of outer membrane
and periplasmic components. They conserve lipophilic polypep-
tides. Only a small number of cytoplasmic components and one
inner membrane protein were predicted. Thus, the proteomic
analysis of GMMA obtained from an OD 45 culture revealed a
similar composition as previously seen in proteomic analyses of
outer membrane particles that were obtained from cultures at
early logarithmic phase to avoid impurities by cytoplasmic proteins
[10,13].
In accordance with previous reports [15,17] GMMA were
highly immunogenic in mice with titers around 1:100,000 after
administration of 2 mg of GMMA with and without adjuvant. A
10-fold lower dosage of GMMA (without adjuvant) resulted in
only a 3-fold reduction and still very high antibody titers
suggesting that low amounts of GMMA might be sufficient for
vaccination. GMMA from the msbB mutant S. sonnei strain did not
show a difference in immunogenicity which was expected due to a
recent report that the resulting lipid A modification does not affect
LPS recognition in mice [42]. Immunoblots confirmed that
antibodies to proteins, including outer membrane proteins OmpA,
OmpX, and YaeT, strongly contributed to the reactivity of the
sera. Interestingly, the outer membrane protein OmpC which
represents about 20% of protein in GMMA was not detected by
sera raised against GMMA. Previously, an immunoproteomic
analysis of isolated outer membrane proteins of Shigella flexneri 2a
[43] also failed to detect OmpC as immunogenic protein. This
could suggest that either OmpC is not immunogenic or that
epitopes potentially recognized by antibodies are not maintained
after SDS-PAGE. This might also apply to other membrane
proteins that were not found by the Western blot analysis even
though not all reactive proteins could be identified.
The msbB mutant strain of Shigella lacking the genes msbB1 and
msbB2 [21] was generated to investigate if the production process
was applicable to GMMA with modified lipid A. A previous
report [21] had shown that these deletions result in the synthesis
of a penta-acylated lipid A instead of a hexa-acylated lipid A in
Shigella [21]. While the S. sonnei –pSS DtolR DmsbB mutant grows
in rich media at 37uC temperature, its growth is impaired in the
chemically defined medium developed for fermentation at 37uC
but shows a normal growth in this medium at 30uC. Previously,
Figure 5. Shigella sonnei DtolR DgalU GMMA proteome. The 61
GMMA-associated proteins that were identified are grouped into
families based on their predicted cellular location, according to
bioinformatic prediction by PSORTb v3.0 [34] and Lipo program [35].
The ‘outer membrane’ column comprises outer membrane proteins
(identified by PSORTb) and lipoproteins predicted to be located in the
outer membrane (identified by Lipo). No lipoproteins associated with
the inner membrane were identified. The distribution shown is based
on the number of identified proteins predicted to be located in a
certain compartment. It does not reflect the protein amount. As
analyzed by densitometry (Fig. 1D), the outer membrane fraction
contains at least 69% of the total protein present in GMMA.
doi:10.1371/journal.pone.0035616.g005
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the K-12 background were reported not to show any growth
defects [21,23]. In contrast, an msbB mutant of the clinical isolate
E. coli H16 formed filaments when grown at 37uC but not at
30uC or when functionally complemented by the cloned msbB
gene [44]. The S. sonnei –pSS DtolR DmsbB mutant strain used in
this study does not form filaments. The reason for the slower
growth at 37uC, especially in defined medium, is not clear and
could be a result of the background of the strain, the
combination of the tolR and msbB mutation, or a suboptimal
composition of the defined medium that can likely be optimized.
Importantly, a comparison of the protein pattern of GMMA
generated from S. sonnei –pSS DtolR at 37uC and 30uC showed
only minor differences in the protein profile visible by SDS-
PAGE indicating that the change in temperature does not have
major effects on GMMA composition.
In summary, we have identified an easy process to produce large
quantities of GMMA from high density culture. GMMA purified
from fermentation are extremely pure particles composed almost
exclusively of outer membrane and periplasmic components. The
simplicity and high yield of the process support its applicability for
large scale manufacturing. We have also shown that this process
can be used with strains genetically modified to reduce reactoge-
nicity or to remove immunodominant antigens, e.g. the O antigen.
While this work focused on Shigella sonnei, we believe that this
technology is an innovative platform for efficient vaccine
manufacturing for Gram-negative bacteria.
Supporting Information
Figure S1 GMMA enrichment and purity after TFF
without diafiltration of the biomass. GMMA were purified
from a 5 L fermentation culture of S. sonnei DtolR DgalU grown in
HTMC at 37uC to OD 39 (fermentation B2 in Table 3) using 2-
step TFF. In the first step, the culture supernatant which contains
the GMMA was separated from the bacteria using a 0.2 mm filter
without further diafiltration of the biomass. To determine the
amount of GMMA in the permeate GMMA were separated from
soluble proteins by ultracentrifugation. After ultracentrifugation,
the pellet (GMMA) was resuspended in the initial volume of the
centrifuged material to normalize all samples to fermentation
volume. Equivalent volumes of the 0.2 mm filtrate before
ultracentrifugation (1), the resuspended GMMA pellet (2), and
the supernatant of the ultracentrifugation (3) were separated by
SDS-PAGE (12% PA) and showed a large amount of soluble
proteins (3) in comparison to GMMA-associated proteins (2) to be
present in the post 0.2 mm TFF permeate. In the second TFF step,
GMMA were separated from soluble proteins using a 0.1 mm
filter. The retentate (4) was analyzed by ultracentrifugation as
described above and was found to contain almost exclusively
GMMA (5) as determined by the strong reduction of soluble
proteins (6). The high recovery rate of 83% in this process (see
Table 3) is reflected in the similar strength of the visible protein
bands in lane 2 (GMMA in the 0.2 mm TFF filtrate) and lane 5
(GMMA in the 0.1 mm retentate).
(TIF)
Figure S2 Reproducibility of purity and protein com-
position of GMMA obtained by the high yield production
process. S. sonnei DtolR DgalU was grown in HTMC at 37uCi na
5 L fermenter to high densities of OD 30 (B1) and OD 39 (B2) and
GMMA were purified using 2-step TFF. To determine the amount
of GMMA in the retentate of the 0.1 mm TFF (purified GMMA)
GMMA were separated from soluble proteins by ultracentrifuga-
tion. After ultracentrifugation, the pellets (GMMA) were resus-
pended in the initial volume of the centrifuged material to
Figure 6. ELISA analysis of sera reactivity against GMMA. Groups 1–6 received 2 mg of GMMA with or without Freund’s adjuvant (FA), group
1) GMMA from S. sonnei DtolR DgalU (grown in HTMC, 37uC), 2) GMMA of group 1 plus FA, 3) GMMA S. sonnei –pSS DtolR (defined medium, 37uC), 4)
GMMA of group 3 plus FA, 5) GMMA from S. sonnei –pSS DtolR DmsbB (defined medium, 30uC), 6) GMMA of group 5 plus FA. Group 7 received 0.2 mg
of GMMA from S. sonnei –pSS DtolR DmsbB. Control groups were immunized with PBS alone (group 8) or FA alone (group 9). Sera from individual
mice obtained 14 days after the third immunization and pooled preimmune sera from each group respectively were assayed in dilutions of 1:1000,
1:10,000, and 1:100,000 on GMMA from S. sonnei 53G –pSS DtolR as coating and arbitrary units were calculated. Data are presented as scatter plots of
ELISA units determined in individual mice (groups 1–9) or of the pooled preimmune sera (pre). The horizontal lines represent the geometric mean.
ELISA units of groups 1–6 receiving 2 mg of GMMA were analyzed using the non-parametric Kruskal-Wallis test to compare the immunogenicity of the
different GMMA to each other and with and without FA. No statistically significant differences were found (n.s.). Reduction of the immunization
dosage of S. sonnei –pSS DtolR DmsbB GMMA to 0.2 mg (group 7) resulted in statistically significant reduction of ELISA units in the sera of the
immunized animals compared to sera of mice immunized with 2 mg of the same GMMA (group 5) as determined by Mann-Whitney test (p=0.0047).
All groups receiving GMMA showed higher S. sonnei –pSS DtolR-specific antibody responses than groups immunized with PBS or FA alone (Mann-
Whitney, p#0.003). For all comparisons a p value smaller than 0.05 was considered to be significant.
doi:10.1371/journal.pone.0035616.g006
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of the retentate before ultracentrifugation (1), the resuspended
GMMA pellet (2), and the supernatant of the ultracentrifugation
(3) were separated by SDS-PAGE (12% PA). The retentates were
found to contain almost exclusively GMMA (2) as determined by
the strong reduction of soluble proteins (3). In addition, the protein
pattern in GMMA from the 2 fermentations was very similar
suggesting good reproducibility of the process. Minor differences
in the visible amount of proteins are highlighted by arrows.
(TIF)
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